Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: DR David Holden

Back to Search
( 2025 ) . COVID-19 exposure risks and protective measures in East London’s healthcare and academic sectors: Insights and applications of GloBody technology for infectious disease monitoring .
( 2024 ) . Effects of cladribine on intrathecal and peripheral B and plasma cells . Clinical and Experimental Immunology vol. 219 , ( 1 ) Article uxae116 ,
( 2024 ) . Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells . Clinical Immunology vol. 269 , Article 110380 , 110380 - 110380 .
( 2024 ) . Effects of cladribine on intrathecal and peripheral B and plasma cells .
( 2024 ) . Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008) . Neurology vol. 102 , ( 7_supplement_1 ) Article 3589 ,
( 2024 ) . Cladribine tablets in Relapsing-Remitting Multiple Sclerosis preferentially target B-cells .
( 2024 ) . Neurofilaments in neurologic disease . Advances in Clinical Chemistry , Elsevier
( 2023 ) . A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis . Multiple Sclerosis Journal vol. 30 , ( 1 ) 63 - 70 .
( 2023 ) . Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 16 , Article 17562864231200627 ,
( 2023 ) . A phase 2 open-label clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with Multiple Sclerosis .
( 2022 ) . Effect of teriflunomide on Epstein–Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study . Multiple Sclerosis and Related Disorders vol. 68 , Article 104377 , 104377 - 104377 .
( 2022 ) . The relationship of cerebrospinal fluid neurofilament levels with magnetic resonance imaging lesion location and disease activity in multiple sclerosis . European Journal of Neurology vol. 29 , ( 9 ) 2754 - 2760 .
( 2022 ) . Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study . MULTIPLE SCLEROSIS AND RELATED DISORDERS . vol. 68 ,
( 2022 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 33 - 34 .
( 2022 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 , Article 103409 , 103409 - 103409 .
( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .
( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . Neurology Neuroimmunology & Neuroinflammation vol. 7 , ( 6 ) Article e880 ,
( 2020 ) . CSF Neurofilament Light Chain for guiding individual treatment decisions in multiple sclerosis . EUROPEAN JOURNAL OF NEUROLOGY . vol. 27 , 475 - 476 .
( 2020 ) . CSF neurofilament light chain testing as an aid to determine treatment strategies in MS . NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION vol. 7 , ( 6 ) Article ARTN e880 ,
( 2020 ) . Effect of teriflunomide on epstein-barr virus shedding in relapsing-remitting multiple sclerosis patients: outcomes from a real-world cohort study . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 277 - 278 .
( 2019 ) . Real Life Evidence for CSF Neurofilaments Light Chain in Clinical Practice. (P5.2-021) . Neurology vol. 92 , ( 15_supplement ) Article P5.2-021 ,
( 2019 ) . Evidence of the utility of CSF neurofilament light chain measurements in people with MS in clinical practice . MULTIPLE SCLEROSIS JOURNAL . vol. 25 , 854 - 854 .
( 2019 ) . Real life Evidence for CSF Neurofilaments Light Chain in Clinical Practice . NEUROLOGY . vol. 92 ,
( 2018 ) . Epstein Barr virus shedding in multiple sclerosis: Similar frequencies of EBV in saliva across separate patient cohorts . Multiple Sclerosis and Related Disorders vol. 25 , 197 - 199 .
( 2018 ) . A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study . Multiple Sclerosis and Related Disorders vol. 24 , 123 - 128 .
( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study biomarker outcome results . MULTIPLE SCLEROSIS JOURNAL . vol. 22 , 188 - 189 .
( 2016 ) . Phase 2 baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study results . MULTIPLE SCLEROSIS JOURNAL . vol. 22 , 188 - 188 .
( 2015 ) . Pilot baseline versus treatment clinical trial of the HIV drug raltegravir in patients with active relapsing remitting multiple sclerosis: the INSPIRE study . MULTIPLE SCLEROSIS JOURNAL . vol. 21 , 162 - 162 .
( 2009 ) . Natural killer cell status in multiple sclerosis and its association with interferon beta-1a treatment . MULTIPLE SCLEROSIS . vol. 15 , S73 - S73 .
Back to Search